The main acute myeloid leukemia treatments are intensive chemotherapy (usually the “7+3” combination of cytarabine and an anthracycline), lower-intensity regimens such as venetoclax with azacitidine for people who cannot tolerate intensive therapy, targeted drugs for specific mutations like FLT3 and IDH, and allogeneic stem cell transplant for those at higher risk of relapse. Which of these you receive depends mainly on your leukemia’s genetic profile, your age, and your overall fitness.
In my practice, the first conversation after an AML diagnosis is rarely about a single drug. It is about a plan: how to get into remission, how to stay there, and how to keep you as well as possible along the way. This guide walks through that plan step by step.
What AML Is and Why Treatment Is Urgent
Acute myeloid leukemia (AML) is one of the hematological cancers. It arises when immature myeloid cells, called blasts, acquire genetic changes that make them multiply without maturing. They crowd out normal blood production in the marrow, causing bone marrow failure: anemia, low platelets, and a shortage of working white cells.
Because AML progresses over days to weeks, treatment usually begins soon after diagnosis. Known risk factors include older age, prior chemotherapy or radiation, exposure to benzene, smoking, and some earlier blood disorders such as myelodysplastic syndromes, though most people have no identifiable cause.
Tests That Shape the Treatment Plan
A complete blood count often shows anemia, low platelets, and blasts in the blood. Diagnosis is confirmed by bone marrow aspiration and biopsy, which usually show a marrow packed with blasts, traditionally 20 percent or more of the cells, or fewer when certain defining genetic changes are present.
The most important results for treatment are cytogenetics (chromosome analysis) and molecular testing for mutations such as FLT3, NPM1, IDH1, IDH2, and TP53. These results place the leukemia into favorable, intermediate, or adverse risk groups and reveal whether a targeted drug is an option. Doctors increasingly wait for rapid FLT3 results before starting chemotherapy so the right drug can be added from day one.
Intensive Chemotherapy: Induction and Consolidation
For people fit enough to tolerate it, treatment proceeds in two phases.
Induction
The classic induction regimen is “7+3”: seven days of continuous-infusion cytarabine plus three days of an anthracycline such as daunorubicin or idarubicin. The goal is complete remission, meaning fewer than 5 percent blasts in the marrow with recovery of normal blood counts. Induction requires a hospital stay of several weeks while counts recover.
For certain subtypes, a modified version is used. CPX-351, a liposomal formulation that packages cytarabine and daunorubicin together, is used for AML arising from a prior blood disorder or after previous cancer therapy.
Consolidation
Remission is not cure; undetectable leukemia cells remain. Consolidation therapy aims to eliminate them. Depending on risk, this means several cycles of intermediate- or high-dose cytarabine, or proceeding to a stem cell transplant. Some patients then receive maintenance therapy, such as oral azacitidine, to lower relapse risk.
Lower-Intensity and Targeted Treatments
Many people with AML are older or have other health conditions that make intensive chemotherapy too risky. For them, the combination of venetoclax (a BCL-2 inhibitor) with a hypomethylating agent, azacitidine or decitabine, has become a standard of care that can be given largely as an outpatient.
Targeted drugs are matched to specific mutations and can be combined with chemotherapy or used alone:
| Target | Example drugs | Where they are used |
|---|---|---|
| FLT3 mutation | Midostaurin, quizartinib, gilteritinib | Added to induction for newly diagnosed FLT3-positive AML; gilteritinib for relapsed disease |
| IDH1 mutation | Ivosidenib | Newly diagnosed unfit patients (often with azacitidine) or relapsed disease |
| IDH2 mutation | Enasidenib | Relapsed or refractory AML |
| CD33 surface protein | Gemtuzumab ozogamicin | Added to chemotherapy, especially in favorable-risk AML |
| KMT2A rearrangement or NPM1 mutation | Menin inhibitors such as revumenib | Relapsed or refractory AML |
| PML-RARA (acute promyelocytic leukemia) | All-trans retinoic acid plus arsenic trioxide | First-line treatment of APL, often without conventional chemotherapy |
Acute promyelocytic leukemia (APL) deserves special mention. It is a medical emergency because of its bleeding risk, but with ATRA and arsenic trioxide it is now among the most curable forms of leukemia.
Stem Cell Transplant and Newer Immune Therapies
Allogeneic hematopoietic stem cell transplantation replaces the diseased marrow with stem cells from a matched sibling, unrelated, or partially matched (haploidentical) donor. Its power comes largely from the graft-versus-leukemia effect, in which donor immune cells attack residual leukemia. It is generally offered in first remission to people with intermediate- or adverse-risk disease, or with persistent measurable residual disease (MRD), who are fit enough for it.
Transplant carries serious risks, including graft-versus-host disease and infection, so the decision balances relapse risk against transplant risk. CAR T-cell therapy and other immune approaches are being studied in AML but are not yet standard, largely because AML targets are also found on healthy blood cells.
For a broader look at how these therapies fit alongside treatments for other leukemias, see our overview of leukemia treatments and management and the leukemia guide.
Supportive Care and When to See a Doctor
Supportive care is part of every AML treatment plan. It includes red cell and platelet transfusions, preventive antibiotics and antifungals during periods of low neutrophils, management of tumor lysis syndrome at the start of therapy, and attention to nutrition, mood, and fatigue.
During treatment, contact your team or go to the emergency department immediately if you have:
- A fever of 38.0 °C (100.4 °F) or higher, or shaking chills
- New bleeding, black stools, or widespread bruising or tiny red spots (petechiae)
- Breathlessness, chest pain, or confusion
- Inability to keep fluids down
Outside of treatment, persistent fatigue, frequent infections, unexplained bruising, and pallor warrant a blood count with your doctor.
Frequently Asked Questions
Is AML curable?
Yes, AML can be cured, particularly in younger patients and those with favorable genetic features or who undergo a successful transplant. For others, treatment aims to control the disease for as long as possible with good quality of life. Your genetic results and response to treatment give the most useful picture of your own outlook.
How long does AML treatment take?
Intensive induction and consolidation typically take several months. Lower-intensity regimens such as venetoclax with azacitidine are given in monthly cycles that continue as long as they are working and tolerated. Transplant adds a recovery period of many months.
What does “refractory” or “relapsed” AML mean?
Refractory AML does not go into remission after induction, while relapsed AML returns after a remission. Both are treated with salvage therapy, often a targeted drug if a matching mutation is present, followed by transplant where possible.
Can older adults receive effective AML treatment?
Yes. Age alone does not rule out treatment. Venetoclax-based and targeted therapies have given older and less fit patients effective options that were not available in the past, and some fit older adults still receive intensive therapy or reduced-intensity transplant.
